493 related articles for article (PubMed ID: 29657070)
1. Inclusion of the murine IgGκ signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.
Fonseca JA; McCaffery JN; Caceres J; Kashentseva E; Singh B; Dmitriev IP; Curiel DT; Moreno A
Vaccine; 2018 May; 36(20):2799-2808. PubMed ID: 29657070
[TBL] [Abstract][Full Text] [Related]
2. A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.
Fonseca JA; McCaffery JN; Kashentseva E; Singh B; Dmitriev IP; Curiel DT; Moreno A
Vaccine; 2017 May; 35(24):3239-3248. PubMed ID: 28483199
[TBL] [Abstract][Full Text] [Related]
3. A Plasmodium vivax Plasmid DNA- and Adenovirus-Vectored Malaria Vaccine Encoding Blood-Stage Antigens AMA1 and MSP1
Obaldia N; Stockelman MG; Otero W; Cockrill JA; Ganeshan H; Abot EN; Zhang J; Limbach K; Charoenvit Y; Doolan DL; Tang DC; Richie TL
Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179404
[TBL] [Abstract][Full Text] [Related]
4. Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.
de Camargo TM; de Freitas EO; Gimenez AM; Lima LC; de Almeida Caramico K; Françoso KS; Bruna-Romero O; Andolina C; Nosten F; Rénia L; Ertl HCJ; Nussenzweig RS; Nussenzweig V; Rodrigues MM; Reyes-Sandoval A; Soares IS
Sci Rep; 2018 Jan; 8(1):1118. PubMed ID: 29348479
[TBL] [Abstract][Full Text] [Related]
5. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles.
Gimenez AM; Salman AM; Marques RF; López-Camacho C; Harrison K; Kim YC; Janse CJ; Soares IS; Reyes-Sandoval A
Sci Rep; 2021 Sep; 11(1):17928. PubMed ID: 34504134
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine.
Alves E; Salman AM; Leoratti F; Lopez-Camacho C; Viveros-Sandoval ME; Lall A; El-Turabi A; Bachmann MF; Hill AV; Janse CJ; Khan SM; Reyes-Sandoval A
Clin Vaccine Immunol; 2017 Apr; 24(4):. PubMed ID: 28179403
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of synthetic peptide constructs based on PvMSP9
Rodrigues-da-Silva RN; Correa-Moreira D; Soares IF; de-Luca PM; Totino PRR; Morgado FN; Oliveira Henriques MDG; Peixoto Candea AL; Singh B; Galinski MR; Moreno A; Oliveira-Ferreira J; Lima-Junior JDC
Vaccine; 2019 Jan; 37(2):306-313. PubMed ID: 30509693
[TBL] [Abstract][Full Text] [Related]
8. Long-term humoral and cellular immune responses elicited by a heterologous Plasmodium vivax apical membrane antigen 1 protein prime/adenovirus boost immunization protocol.
Bouillet LÉ; Dias MO; Dorigo NA; Moura AD; Russell B; Nosten F; Renia L; Braga EM; Gazzinelli RT; Rodrigues MM; Soares IS; Bruna-Romero O
Infect Immun; 2011 Sep; 79(9):3642-52. PubMed ID: 21730090
[TBL] [Abstract][Full Text] [Related]
9. A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.
Fonseca JA; Cabrera-Mora M; Kashentseva EA; Villegas JP; Fernandez A; Van Pelt A; Dmitriev IP; Curiel DT; Moreno A
PLoS One; 2016; 11(4):e0154819. PubMed ID: 27128437
[TBL] [Abstract][Full Text] [Related]
10. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.
Draper SJ; Biswas S; Spencer AJ; Remarque EJ; Capone S; Naddeo M; Dicks MD; Faber BW; de Cassan SC; Folgori A; Nicosia A; Gilbert SC; Hill AV
J Immunol; 2010 Dec; 185(12):7583-95. PubMed ID: 21098232
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
[TBL] [Abstract][Full Text] [Related]
12. A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.
Cabrera-Mora M; Fonseca JA; Singh B; Zhao C; Makarova N; Dmitriev I; Curiel DT; Blackwell J; Moreno A
J Immunol; 2016 Oct; 197(7):2748-61. PubMed ID: 27574299
[TBL] [Abstract][Full Text] [Related]
13. A two-dose viral-vectored
Yamamoto Y; Fabbri C; Okuhara D; Takagi R; Kawabata Y; Katayama T; Iyori M; Hasyim AA; Sakamoto A; Mizukami H; Shida H; Lopes S; Yoshida S
Front Immunol; 2024; 15():1372584. PubMed ID: 38745665
[TBL] [Abstract][Full Text] [Related]
14. Induction of Multifunctional Broadly Reactive T Cell Responses by a Plasmodium vivax Circumsporozoite Protein Recombinant Chimera.
Cabrera-Mora M; Fonseca JA; Singh B; Oliveira-Ferreira J; Lima-Junior Jda C; Calvo-Calle JM; Moreno A
Infect Immun; 2015 Sep; 83(9):3749-61. PubMed ID: 26169267
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of a plasmid DNA vaccine encoding 42kDa fragment of Plasmodium vivax merozoite surface protein-1.
Sheikh IH; Kaushal DC; Chandra D; Kaushal NA
Acta Trop; 2016 Oct; 162():66-74. PubMed ID: 27311385
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.
Lumsden JM; Pichyangkul S; Srichairatanakul U; Yongvanitchit K; Limsalakpetch A; Nurmukhambetova S; Klein J; Bertholet S; Vedvick TS; Reed SG; Sattabongkot J; Bennett JW; Polhemus ME; Ockenhouse CF; Howard RF; Yadava A
Infect Immun; 2011 Sep; 79(9):3492-500. PubMed ID: 21690242
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.
Teixeira LH; Tararam CA; Lasaro MO; Camacho AG; Ersching J; Leal MT; Herrera S; Bruna-Romero O; Soares IS; Nussenzweig RS; Ertl HC; Nussenzweig V; Rodrigues MM
Infect Immun; 2014 Feb; 82(2):793-807. PubMed ID: 24478093
[TBL] [Abstract][Full Text] [Related]
19. A Multi-Stage
McCaffery JN; Fonseca JA; Singh B; Cabrera-Mora M; Bohannon C; Jacob J; Arévalo-Herrera M; Moreno A
Front Cell Infect Microbiol; 2019; 9():135. PubMed ID: 31119106
[TBL] [Abstract][Full Text] [Related]
20. Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein.
Almeida AP; Dias MO; Vieira Cde A; Chávez-Olórtegui C; Gazzineli RT; Rodrigues MM; Fujiwara RT; Bruna-Romero O
Vaccine; 2014 Apr; 32(19):2181-7. PubMed ID: 24582631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
